Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX plus bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis

被引：0
|
作者：
Peria, F. M. [1 ]
Ungari, A. Q. [1 ]
Dos Santos, F. N. [1 ]
Lins-Almeida, T. [2 ]
Nunes, A. A. [1 ]
机构：
[1] Univ Sao Paulo, Fac Med, HCRP Hosp Clin, Internal Med Div Oncol, Ribeirao Preto, Brazil
[2] Univ Sao Paulo, Fac Med, HCRP Hosp Clin, Internal Med, Ribeirao Preto, Brazil
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw387.29
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1393p
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school
    Andrea Queiróz Ungari
    Leonardo Régis Leira Pereira
    Altacílio Aparecido Nunes
    Fernanda Maris Peria
    [J]. BMC Cancer, 17
  • [2] Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school
    Ungari, Andrea Queiroz
    Leira Pereira, Leonardo Regis
    Nunes, Altacilio Aparecido
    Peria, Fernanda Maris
    [J]. BMC CANCER, 2017, 17
  • [3] EFFECTIVENESS OF CHEMOTHERAPY WITH OXALIPLATIN, CAPECITABINE AND BEVACIZUMAB (XELOX plus BEV) IN SECOND LINE THERAPY OF METASTATIC COLORECTAL CANCER (MCRC)
    Arzykulov, Z.
    Chichua, N.
    Smagulova, K.
    Khamidullina, G.
    Mukanova, S.
    Suriya, K.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 32 - 32
  • [4] COST-UTILITY ANALYSIS OF XELOX PLUS BEVACIZUMAB VERSUS XELOX FOR METASTATIC COLORECTAL CANCER TREATMENT IN THAILAND
    Wanitphisitphan, C.
    Kositamongkol, C.
    Korphaisarn, K.
    Akewanlop, C.
    Srimuninnimit, V
    Phisalprapa, P.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S53 - S53
  • [5] Capecitabine and oxaliplatin (XELOX) as first line treatment for patients with metastatic colorectal cancer (MCRC)
    Karacetin, D.
    Maral, O.
    Yalcyn, B.
    Okten, B.
    Incekara, O.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 73 - 73
  • [6] Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer
    Uchima, Yasutake
    Nishii, Takafumi
    Iseki, Yasuhito
    Ishii, Mariko
    Hiramatsu, Soichiro
    Iwauchi, Takehiko
    Morimoto, Junya
    Kosaka, Kinshi
    Tei, Seika
    Takeuchi, Kazuhiro
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (01) : 134 - 138
  • [7] Bi-weekly XELOX (capecitabine/oxaliplatin) plus bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): PHOENIX trial
    Nagata, N.
    Okada, T.
    Okazaki, S.
    Sato, S.
    Kin, H.
    Nakamura, M.
    Kunieda, K.
    Oba, K.
    Sakamoto, J.
    Mishima, H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S559 - S559
  • [8] XELOX (capecitabine plus oxaliplatin):: Active first-line therapy for patients with metastatic colorectal cancer
    Cassidy, J
    Tabernero, J
    Twelves, C
    Brunet, R
    Butts, C
    Conroy, T
    Debraud, F
    Figer, A
    Grossmann, J
    Sawada, N
    Schöffski, P
    Sobrero, A
    Van Cutsem, E
    Diaz-Rubio, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) : 2084 - 2091
  • [9] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer:The OBELIX study
    Lorenzo Antonuzzo
    Elisa Giommoni
    Davide Pastorelli
    Tiziana Latiano
    Ida Pavese
    Domenico Azzarello
    Michele Aieta
    Ilaria Pastina
    Francesca Di Fabio
    Alessandro Bertolini
    Domenico Cristiano Corsi
    Selene Mogavero
    Valentina Angelini
    Mario Pazzagli
    Francesco Di Costanzo
    [J]. World Journal of Gastroenterology, 2015, (23) : 7281 - 7288
  • [10] Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer
    Karacetin, D.
    Yalcin, B.
    Okten, B.
    Ozturk, S.
    Maral, O.
    Incekara, O.
    [J]. JOURNAL OF BUON, 2009, 14 (04): : 605 - 608
12345